



Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

Eugenio Mercuri^{1,2} · Andrés Nascimento Osorio³ · Francesco Muntoni^{4,5} · Filippo Buccella⁶ · Isabelle Desguerre⁷ · Janbernd Kirschner⁸ · Már Tulinius⁹ · Maria Bernadete Dutra de Resende¹⁰ · Lauren P. Morgenroth¹¹ · Heather Gordish-Dressman¹² · Shelley Johnson¹³ · Allan Kristensen¹³ · Christian Werner¹⁴ · Panayiota Trifillis¹³ · Erik K. Henricson¹⁵ · Craig M. McDonald¹⁵ on behalf of the STRIDE and CINRG DNHS investigators

Published online: 17 July 2023
© The Author(s) 2023

Correction to: Journal of Neurology
<https://doi.org/10.1007/s00415-023-11687-1>

The original version of this article unfortunately contained a mistake. There are 2 data errors in the results section of the abstract.

In abstract, first sentence of the results section should read as As of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 5.4 (3.1) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (566.8) days.

The original article can be found online at <https://doi.org/10.1007/s00415-023-11687-1>.

✉ Eugenio Mercuri
eugeniomaria.mercuri@unicatt.it

¹ Department of Pediatric Neurology, Catholic University, Rome, Italy

² Centro Clinico Nemo, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy

³ Neuromuscular Unit, Department of Neurology and Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu, Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

⁴ UCL Great Ormond Street Institute of Child Health, London, UK

⁵ National Institute for Health Research, Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London, London, UK

⁶ Parent Project APS, Rome, Italy

⁷ Hôpital Necker-Enfants Malades, Paris, France

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

⁸ Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany

⁹ Department of Pediatrics, Gothenburg University, Queen Silvia Children's Hospital, Gothenburg, Sweden

¹⁰ Department of Neurology, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil

¹¹ Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS), Pittsburgh, PA, USA

¹² Center for Genetic Medicine, Children's National Health System and the George Washington, Washington, DC, USA

¹³ PTC Therapeutics Inc., South Plainfield, NJ, USA

¹⁴ PTC Therapeutics Germany GmbH, Frankfurt, Germany

¹⁵ University of California Davis School of Medicine, Davis, CA, USA